MD Anderson Cancer Center Publication Shows How Bionano’s Saphyr System Can Significantly Reduce Time to Actionable Results for Myelodysplastic Syndrome Patients
MDS is a precursor to Acute Myeloid Leukemia and structural variation analysis is important for clinical management of patients with MDS.
- MDS is a precursor to Acute Myeloid Leukemia and structural variation analysis is important for clinical management of patients with MDS.
- Several tests are run sequentially after initial data analysis to confirm gene-specific variants, leading to a diagnostic process that can span several weeks.
- In this study, Dr. Kanagal-Shamanna evaluated the performance of OGM in a series of 12 previously well-characterized MDS cases using clinical bone marrow samples.
- Erik Holmlin, PhD, CEO of Bionano Genomics, commented: The MD Anderson Cancer Center is one of the worlds most important cancer research and treatment centers.